Prevalence and characteristics of sellar masses in the city of Al Ain, United Arab Emirates: 2010 to 2016

Ann Saudi Med. 2020 Mar-Apr;40(2):105-112. doi: 10.5144/0256-4947.2020.105. Epub 2020 Apr 2.

Abstract

Background: The prevalence of sellar masses (SMs) is reported in Europe and North America but only limited data are available from the Middle East and North Africa (MENA) region.

Objectives: Assess the prevalence and characteristics of SMs in Al Ain city, United Arab Emirates.

Design: Retrospective, descriptive multicenter study.

Setting: Three endocrine centers in Al Ain.

Patients and methods: All patients diagnosed with SMs in the city of Al Ain, Emirate of Abu Dhabi, between 2011 and 2016 were evaluated. Cases were identified using ICD 9 and 10 codes and demographic and clinical data were collected. The prevalence rate was calculated for patients alive and residing in Al Ain city until 31 December 2016.

Main outcome measures: Clinical presentations and prevalence rate.

Sample size: 272.

Results: The mean (SD) age on presentation was 40.8 (14.3) years (range: 6-114 years, median: 40.0). The 170 (61.8%) females and 128 (46.5%) were native citizens of the United Arab Emirates. Two hundred and forty five (90%) patients had pituitary adenomas (PAs) while 27 (10%) had non-pituitary sellar lesions. The four most common SMs were prolactinoma (n=139, 51.1%), nonfunctioning adenoma (NFA) (n= 69, 25.4%), somatotroph adenoma (n=32, 11.8%) and craniopharyngioma (n=15, 5.5%). Patients with prolactinoma, corticotroph adenoma, and Rathke's cleft cyst had small sellar masses (<1 centimeter) while the majority of patients with other SMs had macroadenomas. Hypogonadism and growth hormone deficiency was present in 41.8% and 20.5% of the patients, respectively. Of 268 patients with available data, 82 patients underwent surgery while 25 patients received radiotherapy. At the end of 2016, 197 patients were residing in Al Ain city. The overall prevalence of SMs was 25.7/100 000 with PAs constituting most of these masses (n=177) for a prevalence of 23.1/100 000.

Conclusions: This is the first study of SMs in the United Arab Emirates and the MENA region. Prolactinoma and NFA were the two most common SMs. Further studies are needed to explore the reasons for the lower prevalence of SMs in our region compared with other countries.

Limitations: Retrospective design, relatively small sample size.

Conflict of interest: None.

MeSH terms

  • ACTH-Secreting Pituitary Adenoma / epidemiology
  • ACTH-Secreting Pituitary Adenoma / pathology
  • ACTH-Secreting Pituitary Adenoma / physiopathology
  • ACTH-Secreting Pituitary Adenoma / therapy
  • Adenoma / epidemiology*
  • Adenoma / pathology
  • Adenoma / physiopathology
  • Adenoma / therapy
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Central Nervous System Cysts / epidemiology*
  • Central Nervous System Cysts / pathology
  • Central Nervous System Cysts / physiopathology
  • Central Nervous System Cysts / therapy
  • Child
  • Craniopharyngioma / epidemiology*
  • Craniopharyngioma / pathology
  • Craniopharyngioma / physiopathology
  • Craniopharyngioma / therapy
  • Female
  • Growth Hormone / deficiency
  • Growth Hormone-Secreting Pituitary Adenoma / epidemiology
  • Growth Hormone-Secreting Pituitary Adenoma / pathology
  • Growth Hormone-Secreting Pituitary Adenoma / physiopathology
  • Growth Hormone-Secreting Pituitary Adenoma / therapy
  • Humans
  • Hypogonadism / physiopathology
  • Hypopituitarism / epidemiology
  • Male
  • Middle Aged
  • Neurosurgical Procedures
  • Pituitary Neoplasms / epidemiology*
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / physiopathology
  • Pituitary Neoplasms / therapy
  • Prevalence
  • Prolactinoma / epidemiology
  • Prolactinoma / pathology
  • Prolactinoma / physiopathology
  • Prolactinoma / therapy
  • Radiotherapy
  • Sella Turcica
  • Tumor Burden
  • United Arab Emirates / epidemiology
  • Young Adult

Substances

  • Growth Hormone

Grants and funding

None.